Nefazodone - PharmaKB

Nefazodone

Nefazodone (nefazodone) is a small molecule pharmaceutical. Nefazodone was first approved as Serzone on 1994-12-22. It is used to treat depressive disorder and post-traumatic stress disorders in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter, 5-hydroxytryptamine receptor 2A, and sodium-dependent noradrenaline transporter. In addition, it is known to target cytochrome P450 3A4.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
mental disorders	D001523

Trade Name

FDA

EMA

Nefazodone (discontinued: Nefazodone, Serzone)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Nefazodone hydrochloride

Tradename	Company	Number	Date	Products
SERZONE	Bristol Myers Squibb	N-020152 DISCN	1994-12-22	6 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
nefazodone hydrochloride	ANDA	2025-09-04

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
post-traumatic stress disorders	EFO_0001358	D013313	F43.1
depressive disorder	EFO_1002014	D003866	F32.A

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

N: Nervous system drugs

— N06: Psychoanaleptics

— N06A: Antidepressants

— N06AX: Other antidepressants in atc

— N06AX06: Nefazodone

HCPCS

Code	Description
G9507	Documentation that the patient is on a statin medication or has documentation of a valid contraindication or exception to statin medications; contraindications/exceptions that can be defined by diagnosis codes include pregnancy during the measurement period, active liver disease, rhabdomyolysis, end stage renal disease on dialysis and heart failure; provider documented contraindications/exceptions include breastfeeding during the measurement period, woman of child-bearing age not actively taking birth control, allergy to statin, drug interaction (hiv protease inhibitors, nefazodone, cyclosporine, gemfibrozil, and danazol) and intolerance (with supporting documentation of trying a statin at least once within the last 5 years or diagnosis codes for myostitis or toxic myopathy related to drugs)

Code

Description

G9507

Documentation that the patient is on a statin medication or has documentation of a valid contraindication or exception to statin medications; contraindications/exceptions that can be defined by diagnosis codes include pregnancy during the measurement period, active liver disease, rhabdomyolysis, end stage renal disease on dialysis and heart failure; provider documented contraindications/exceptions include breastfeeding during the measurement period, woman of child-bearing age not actively taking birth control, allergy to statin, drug interaction (hiv protease inhibitors, nefazodone, cyclosporine, gemfibrozil, and danazol) and intolerance (with supporting documentation of trying a statin at least once within the last 5 years or diagnosis codes for myostitis or toxic myopathy related to drugs)

Clinical

Clinical Trials

6 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Anxiety disorders	D001008	EFO_0006788	F41.1	—	—	—	1	—	1
Social phobia	D000072861	EFO_1001917	F40.1	—	—	—	1	—	1

Indications Phases 3

No data

Indications Phases 2

No data

Indications Phases 1

No data

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Nefazodone
INN	nefazodone
Description	Nefazodone is a N-arylpiperazine, a N-alkylpiperazine, a member of triazoles, a member of monochlorobenzenes and an aromatic ether. It has a role as an antidepressant, a serotonergic antagonist, a serotonin uptake inhibitor, an alpha-adrenergic antagonist and an analgesic.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1

Identifiers

PDB	—
CAS-ID	83366-66-9
RxCUI	—
ChEMBL ID	CHEMBL623
ChEBI ID	7494
PubChem CID	4449
DrugBank	DB01149
UNII ID	59H4FCV1TF (ChemIDplus, GSRS)

Target

Agency Approved

SLC6A4

HTR2A

SLC6A2

Organism

Homo sapiens

Gene name

SLC6A4

Gene synonyms

HTT, SERT

NCBI Gene ID

6532

Protein name

sodium-dependent serotonin transporter

Protein synonyms

5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4

Uniprot ID

Q5EE02

Mouse ortholog

Slc6a4 (15567)

sodium-dependent serotonin transporter (Q60857)

Alternate

CYP3A4

Organism

Homo sapiens

Gene name

CYP3A4

Gene synonyms

CYP3A3

NCBI Gene ID

1576

Protein name

cytochrome P450 3A4

Protein synonyms

1,4-cineole 2-exo-monooxygenase, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase (sulfoxide-forming), Albendazole sulfoxidase, Cholesterol 25-hydroxylase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, cytochrome P450, family 3, subfamily A, polypeptide 4, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, Cytochrome P450-PCN1, glucocorticoid-inducible P450, Nifedipine oxidase, P450-III, steroid inducible, Quinine 3-monooxygenase, taurochenodeoxycholate 6-alpha-hydroxylase

Uniprot ID

Q9UK50

Mouse ortholog

—

Variants

No data

Financial

Revenue by drug

€

₣

No data

Estimated US medical usage